International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

Frontiers in Endocrinology, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the advancement of research in the fields of endocrinology, diabetes, and metabolism. Established in 2010, this journal has consistently demonstrated its academic excellence, achieving a prominent Q1 quartile ranking in its category as of 2023, and a commendable Scopus rank of #96 out of 244, placing it within the 60th percentile. The journal is committed to disseminating high-quality research that encompasses a wide range of topics within endocrinology, catering to the needs of a diverse audience that includes researchers, medical professionals, and students alike. With the critical goal of fostering knowledge-sharing and collaboration within the scientific community, Frontiers in Endocrinology is an invaluable resource for anyone looking to stay updated on the latest advancements and insights in endocrinology. It operates under a robust open-access model, ensuring that groundbreaking research is accessible to all, thereby driving innovation and progress in this essential field.

The JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, published by Walter de Gruyter GmbH, is a reputable peer-reviewed journal dedicated to advancing the field of pediatric endocrinology and metabolism. Since its inception in 1985, this journal has become a vital resource for professionals and researchers, providing insights into the latest advancements, clinical practices, and foundational research in the care of children with endocrine disorders. With a noted Q3 ranking in Endocrinology, Diabetes and Metabolism, and a robust focus on Pediatrics, Perinatology, and Child Health, it addresses important topics such as hormonal imbalances and metabolic syndromes in young populations. Despite its non-open access status, it continues to play an essential role in bridging the knowledge gap within our understanding of children's health and disease, contributing significantly to the progress in this specialized field.

Archives of Endocrinology Metabolism is a distinguished open-access journal dedicated to advancing the field of endocrinology and metabolism. Published by SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA, this journal has established itself as a vital platform for researchers, clinicians, and scholars since its inception in 2008. With an ISSN of 2359-3997 and E-ISSN of 2359-4292, it aims to disseminate high-quality research articles that explore the latest advancements in endocrinology, diabetes, and metabolism. As of 2023, it has achieved a commendable Q3 ranking in its field, demonstrating its relevancy and increasing visibility among peers. The journal's focus spans various sub-disciplines, including hormonal regulation, metabolic disorders, and innovative therapies, making it an essential resource for both emerging professionals and seasoned experts alike. With a rich repository of research from Brazil and beyond, Archives of Endocrinology Metabolism continuously seeks to contribute to the ongoing dialogue and collaboration within the global scientific community.

Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM is a leading academic journal published by Elsevier that focuses on the dynamic field of endocrinology and metabolism. With an impressive impact factor reflected in its Q1 ranking in both endocrinology and endocrinology, diabetes, and metabolism for 2023, this journal is essential for researchers, healthcare professionals, and students seeking to stay abreast of the most significant developments in clinical practice and research. Covering a wide range of topics within the scope of endocrinology, the journal provides a platform for innovative research, comprehensive reviews, and insightful case studies, all aimed at enhancing patient care and advancing the field. With robust rankings, including a position of 22nd out of 244 in Endocrinology and a 90th percentile ranking in Biochemistry, Genetics, and Molecular Biology, this journal is recognized for its scholarly contribution and relevance. As an open-access journal, it ensures that valuable research is accessible to a global audience, advancing knowledge and clinical practice in endocrinology.

Minerva Endocrinology, published by EDIZIONI MINERVA MEDICA in Italy, serves as a pivotal platform for advancing knowledge in the field of endocrinology, diabetes, and metabolism. With its ISSN 2724-6507 and E-ISSN 2724-6116, the journal has rapidly established a reputable position in academia, achieving impressive rankings such as Q3 in both Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. This enables Minerva Endocrinology to attract a diverse readership, including researchers, healthcare professionals, and students committed to understanding the complexities of endocrine disorders. With annual publications covering breakthroughs and innovative research covering converged years from 2021 to 2024, the journal is devoted to facilitating the dissemination of high-quality studies that advance clinical and laboratory practices. Despite its >Open Access< status, the journal encourages submissions that reflect rigorous scientific inquiry and uphold the highest standards of scholarship, thereby enhancing its role as a significant contributor to the field of internal medicine and endocrinology.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.